VA

Vapotherm IncFRA Vapotherm Stock Report

Last reporting period 30 Jun, 2024

Updated —

Last price

Market cap $B

0.014

Micro

Exchange

XFRA - Deutsche Boerse AG

VA21.F Stock Analysis

VA

Uncovered

Vapotherm Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-42/100

Low score

Market cap $B

0.014

Dividend yield

Shares outstanding

46.193 B

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 261 full-time employees. The company went IPO on 2018-11-14. The company is focused on the care of patients of all ages suffering from the respiratory distress associated with lung diseases, such as chronic obstructive pulmonary disease, congestive heart failure, pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company has five versions of its Precision Flow systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its High Velocity Therapy systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow Hi-VNI system offers connectivity to a hospital’s nurse call system to alert the staff to disruption of the patient’s respiratory support.

View Section: Eyestock Rating